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INTRODUCTION 
Hyperlipidemia, one of the important risk factor of 
atherosclerosis, is an abnormality commonly encountered in 
patients with chronic kidney disease. The increased risk of 
atherosclerotic cardiovascular disease may be due to hyperlipidemia. 
Other risk factors predisposing to cardiovascular disease in chronic 
kidney disease patients include diabetes, hypertension, obesity and 
smoking. 
Dyslipoproteinemia is an additional risk factor for the 
progression of renal insufficiency. It has been shown in a large 
population of patients with chronic kidney disease that the rate of 
progression was significantly higher in hyperlipidemic patients 
compared with normolipidemic patients1. 
The pathogenesis of chronic allograft dysfunction is complex 
and results from various factors. Among them hyperlipidemia is an 
important factor implicated in the development and progression of 
chronic allograft dysfunctions. In an observational study, it was 
found that hypertriglyceridemia and the Lp (a) >30mg/dl before and 
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after transplantation were independent risk factors for chronic 
allograft dysfunction2.  
Factors such as race, gender, age and diabetic status 
potentially confound the interpretation of the lipoprotein profile3. 
Indian studies on lipid abnormalities in chronic kidney 
disease have not been consistent. Sharma et al.,4 Kunde et al.,5 
found no hyperlipidemia whereas Gupta et al.,6 Das et al.,7 
observed hypertriglyceridemia and reduced HDL levels in CKD 
patients as in western studies. In view of inconsistency and limited 
evidence in southern part of this country it was decided to study the 
lipid profile in our patients with chronic kidney disease. 
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AIMS OF THE  STUDY 
1. To estimate various lipid profile abnormalities in Chronic 
Kidney Disease patients.       
2. To identify the predominant lipid pattern in chronic kidney 
disease patients. 
3. To study the correlation  between the serum creatinine 
levels and lipid abnormalities in Chronic Kidney Disease. 
4. To estimate the prevalence of Left Vetricular Hypertrophy 
and Ischemic Changes in patients with chronic kidney 
disease. 
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REVIEW OF LITERATURE 
CHRONIC KIDNEY DISEASE DEFINITION:8,9 
K/DOQI - Kidney Disease Outcome Quality Initiative 
definition of CKD is 
1. Kidney damage for >3 months is defined by structural 
or functional abnormalities of the kidney with or 
without reduction in GFR manifest either by 
a. pathological abnormalities or 
b. Markers of kidney damage including abnormalities 
of composition of blood or urine or abnormalities in 
imaging tests. 
2. GFR <60ml/min/1.73m2 for >3 months with or without 
kidney damage. 
HISTORY: 
The word “Uremia” is coined by Piorry & L.Heritier in 1840. 
Association between lipid abnormalities and pathogenesis of renal 
disease was first suggested by virchow in 1860. He described 
extensive fatty degeneration in autopsy tissue from patients with 
Bright’s disease. 
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EPIDEMIOLOGY: 
In India, with a population of one billion and an estimated 
incidence of ESRD of 100 per Million Population, approximately 
100,000 patients develop ESRD each year. Of these 90% never see 
a nephrologist. Of the 10,000 patients who do consult a 
nephrologist renal replacement therapy started in 90%; the other 
10% are unable to afford any form of renal replacement therapy10. 
The majority of the 9000 patients who receive renal 
replacement therapy are begun on hemodialysis. Of the 8500 
patients, who are on hemodialysis, about 60% lost their follow-up 
within 3 months. Approximately 9-13% of patients die within one 
year while on treatment11,12. 
About 17-23% of patients undergoing renal transplantation 
should be on dialysis for 2-3 months for pre-transplant stabilisation. 
Although 4% of patients remain on maintenance HD, very few stay 
on maintenance HD longer than 24 months11,12.  
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Patients mobilise the resources for the expenditure from the 
following13: 
1. 4% - Pooled family resources 
2. 60% - Employer 
3. 20% - Selling property and jewels 
4. 20% - Loans 
ETIOLOG Y 
Common causes of ESRD in India are 
Disease % Center A12 Center B14 Center C15 
CGN (Chronic glomerulo nephritis) 28.6 36.64 18.20 
Diabetic nephropathy 23.2 23.84 26.76 
Chronic interstitial nephritis 16.5 14.35 21.05 
Hypertensive nephrosclerosis 4.1 13.4 10.06 
Obstructive nephropathy 6.4 – 1.22 
Adult polycystic kidney disease 2.0 3.53 2.07 
Unknown 16.2 3.76 – 
In developing countries like India, majority of patients die 
without receiving any form of dialysis. The number of patients 
accepted by dialysis programs is about 
80 pmp  - Egypt16 
20 pmp - Malaysia17 
3-5 pmp - India & China18 
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PATHOPHYSIOLOGY OF CHRONIC KIDNEY DISEASE19 
The pathophysiology of CKD involves two broad sets of 
mechanisms of damage (1) Initiating mechanisms specific to 
underlying etiology (Immune complexes and mediators of 
inflammation in certain type of glouerulonephritis, or toxin 
exposure in certain diseases of the renal tubules and interstitium) 
and 2) a set of progressive mechanisms involving hyperfiltration 
and hypertrophy of the remaining viable nephrons, that are a 
common consequence following long term reduction of renal mass, 
irrespective of underlying etiology. The responses to reduction in 
nephron number are mediated by vasoactive hormones, cytokines, 
and growth factors. Eventually, these short term adaptations of 
hypertrophy and hyperfiltration become maladaptive as the 
increased pressure and flow predisposes to sclerosis and dropout of 
remaining nephrons. Increased intrarenal activity of the renin-
angiotensin axis appears to contribute both to initial adaptive 
hyperfiltration and to the subsequent maladaptive hypertrophy and 
sclerosis, the latter, in part, owing to the stimulation of 
transforming growth factor β;(TGF β). This process explains why a 
reduction in renal mass from an isolated insult may lead to a 
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progressive decline in renal function over many years. 
Stages of CKD19 
National Kidney Foundation (KDOQI) laid guidelines for the 
definition of stage of CKD. 
Stages GFR, ml/min per 1.73m2 
0 >90a 
1 >90b 
2 60-89 
3 30-59 
4 16-29 
5 <15 
a) With risk factors for CKD (HTN, DM, autoimmune 
disease, old age, African ancestry, family history, H/o 
ARF, Proteinuria, abnormal urinary sediment, abnormal 
urinary test) 
b) With demonstrated kidney damage e.g. persistent 
proteinuria, abnormal urinary sediment, abnormal blood 
and urine chemistry, abnormal imaging studies. 
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CLINICAL FEATURES: 
Fluid and electrolyte disturbances 
• Volume expansion 
• Hyponatremia 
• Hyperkalemia 
• Hyperphosphatemia 
Endocrine - Metabolic disturbances 
• Secondary hyperparathyroidism 
• Adynamic bone disease 
• Vit. D deficient osteomalacia 
• Carbohydrate resistance 
• Hyperuricemia 
• Hypertriglyceridemia 
• Increased Lp (a) levels 
• Decreased high density lipoprotein level 
• Malnutrition 
• Amenorrhea ,infertility and sexual dysfunction 
• β2 microglobulin associated amyloidosis 
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Neuromuscular Disturbances 
• Fatigue 
• Sleep disorders 
• Headache 
• Impaired mentation 
• Lethargy 
• Asterixis 
• Muscular rigidity 
• Peripheral neuropathy 
• Restless leg syndrome 
• Myoclonus 
• Seizures 
• Coma 
• Muscle cramps 
• Dialysis disequilibrium syndrome 
• Myopathy 
 
Cardiovascular and pulmonary complication 
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• Arterial hypertension 
• Congestive heart failure or pulmonary edema 
• Pericarditis 
• Hypertropic or dilated cardiomyopathy 
• Uremic lung 
• Accelerated atherosclerosis 
• Hypotension and arrythmias 
• Vascular calcification 
Dermatologic Disturbances 
• Pallor 
• Hyperpigmentation 
• Pruritus 
• Ecchymoses 
• Fibrosing dermopathy 
• Uremic frost 
 
 
Gastro Intestinal disturbances 
 12
• Anorexia 
• Nausea and vomiting 
• Gastroenteritis 
• Peptic ulcer 
• Gastrointestinal bleeding 
• Idiopathic ascites 
• Peritonitis 
Hematologic and Immunologic disturbances 
• Anemia 
• Lymphocytopenia 
• Bleeding diathesis 
• Increased susceptibility to infection 
• Leukopenia 
• Thrombocytopenia 
 
Treatment 
The optimal timing of therapy is usually well before a 
measurable decline in GFR and certainly before CKD is 
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established. 
Clinical Action Plan19 
 GFR ml/min/ 
1.73m2 
Action a 
Kidney damage 
with normal or 
increased GFR 
>90 Diagnosis and treatment, treatment 
of comorbid conditions, slowing 
progression, CVD risk reduction 
Kidney damage 
with mild 
decrease in GFR 
60-89 Estimating progression 
Moderate ↓ GFR 30-59 Evaluating and treating 
complications 
Severe ↓ GFR 15-29 Preparation for kidney replacement 
therapy 
Kidney Failure <15  
(or dialysis) 
Kidney replacement  
(if uremia present) 
a
-includes actions from preceding stages. 
Renal replacement therapy includes both dialysis and 
transplantation. 
Slowing the progression of renal disease in CKD can be 
accomplished by the following. 
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1. Diet - Protein restriction 0.6-0.75g/kg/day 
        - Low salt 60-80mmol/day  
2. Blood pressure control - Bp <130-135/80-85mmHg 
         if proteinuria <1g/24 hr 
         Bp <125/75 mmHg if proteinuria >1g/24 hr 
3. Proteinuria –to  reduce to <1g/24hr 
use an ACE inhibitor or angiotensin receptor antagonist 
4. Glycemic control in DM - Hb AIC < 7% 
5. Dyslipidemia -Control individual lipid fractions 
6. Smoking - cessation 
7. Alcohol - Restriction to less than 2 drinks per day. 
DYSLIPIDEMIA: 
Dyslipidemia is empirically defined as plasma lipids that are 
associated with adverse outcomes such as cardiovascular disease20. 
Normal structure and fuction of lipoprotein:  
Lipoproteins & Apolipoproteins: 
• Lipoproteins consist of lipids and proteins known as 
apolipoproteins (apo) with the main function of 
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transporting water insoluble lipids such as cholesterol 
or triglycerides in plasma, from sites of absorption (gut) 
and/or synthesis (liver) to the sites of utilization 
(peripheral tissues) or processing. 
• In addition to their role in the formation of lipoproteins 
apolipoproteins perform a variety of functions in the 
metabolic conversions of lipoproteins including 
secretion, retardation of premature removal, recognition 
of binding & removal sites and activation of lipolytic 
enzymes. 
Traditionally, lipoproteins are classified on the basis of their 
density properties21 
1. Chylomicrons (<0.94g/ml density) 
2. Very low density (0.94 - 1.006g/ml density) 
3. Intermediate density (1.006 - 1.019 g/ml density) 
4. Low density (1.019 - 1.063 g/ml density) 
5. High Density (1.063 - 1.21 g/ml density) 
LIPOPROTEIN PATHWAYS: 
Lipoprotein pathways are divided into exogenous pathway 
and endogeneous pathway. 
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EXOGENOUS PATHWAY: 
In this pathway chylomicrons transport dietary lipids that are 
absorbed from the intestine via the systemic circulation. 
Chylomicrons are triglyceride rich and normally catabolized within 
minutes by the endothelium - associated lipoprotein lipase (LPL), 
thereby generating free fatty acids (FFA), which are taken up by the 
liver, muscle and adipose tissues. During this catabolic process, 
chylomicrons diminish in size and become chylomicron remnants, 
which are taken up by the liver via the low-density lipoprotein 
(LDL) receptor and the LDL receptor - related protein (LRP). 
ENDOGENOUS PATHWAY 22 
In this pathway, the liver assembles and secretes triglyceride 
- rich VLDL particles, which transport triglycerides from the liver 
to peripheral tissues. After hydrolysis of the triglycerides by LPL 
(Lipoprotein lipase) the VLDL particles are reduced to intermediate 
density lipoproteins which can be taken up by the liver or can be 
further hydrolysed to LDL particles. During this conversion, the 
particles become depleted of triglycerides but retain considerable 
amounts of cholesterol . 
LDL transports cholesterol primarily to hepatocytes but also 
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to peripheral tissues. APO B-100 is responsible for the recognition 
and uptake of LDL by the LDL receptor, which clears 
approximately 60-80% of LDL in normal individuals. The 
remaining LDL is removed by other specific receptors such as LRP 
or by scavenger receptors23. 
Oxidized LDL (OX-LDL) in particular can be taken up by 
scavenger receptors on macrophages and vascular smooth muscle 
cells. When these macrophages become overloaded with cholesterol 
esters, they transform into foam cells, which is a major step in the 
development of atherosclerosis. When LDL becomes lipid depleted 
small dense LDL (sd LDL) is generated which has lower affinity 
for the LDL receptor but is more susceptible to oxidative 
modification. Thus sd LDL is more atherogenic than larger LDL 
particles24. 
High-density lipoprotein plays an important role in reverse 
cholesterol transport, which shuttles cholesterol from peripheral 
cells to the liver an important step that relieves the peripheral cells 
from cholesterol burden25. HDL precursor particles are secreted by 
the liver and intestine and can absorb free cholesterol from cell 
membranes; a process that is mediated by ATP binding 
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cassette transporter-1, apoA-I, apoA-IV. ApoA-I is the major 
apolipoprotein of HDL and activates lecithin: Cholesterol 
acyltransferase  which esterifies the accepted free cholesterol for 
transport.  
By acquisition of additional apolipoproteins, cholesterol 
esters and triglycerides, HDL3 particles are transformed into larger 
HDL2 particles26. Reverse cholesterol transport can take three 
different routes. First large HDL particles with multiple copies of 
Apo E can be taken up by the liver via the LDL receptor. Second, 
the accumulated cholesterol ester from HDL can be selectively 
taken up by the liver mediated by scavenger receptor B127. This 
receptor is expressed primarily in liver and nonplacental 
steroidogenic tissues. Third, cholesterol esters are transferred by 
the cholesteryl ester transfer protein from HDL to triglyceride rich 
lipoproteins. Plasma HDL cholesterol levels are influenced by the 
complexity of these reverse cholesterol transport process. 
Disturbances in the concentration of apoproteins, function of 
enzymes, transport proteins, receptors, other lipoproteins and the 
clearance from plasma can have a major impact on the anti 
atherogenic properties of HDL. 
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Pathophysiology of dyslipidemia in CKD28-31 
Plasma triglycerides are predominantly found in two types of 
lipoproteins in normal individuals. These are chylomicrons which 
are assembled in the intestine for the transport of dietary fatty 
acids, and VLDL, which are produced in the liver for the transport 
of endogenous fatty acids32-34. 
Elevated triglycerides are the consequence of both high 
production rate and a low fractional catabolic rate35. 
Increased production of triglyceride rich lipoproteins is 
possibly due to 
1. Impaired carbohydrate tolerance. 
2. Enhanced hepatic VLDL synthesis. 
Reduced fractional catabolic rate is due to decreased activity 
of two endothelium associated lipases namely lipoprotein lipase and 
hepatic triglyceride lipase which have the primary physiologic 
function of clearing triglycerides into FFA. 
The cause of decreased lipase activities in uremia is thought 
to be depletion of the enzyme pool induced by 
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a) Heparinisation in hemodialysis36. 
b) Increase in the plasma apoc-III/apo-c II ratio37. 
c) Presence of other lipase inhibitors in the plasma. 
Impaired lipase activities in uremic plasma may also be 
caused by a decrease in LPL synthesis as a result of secondary 
hyperparathyroidism or suppressed insulin level38. 
HIGH DENSITY LIPOPROTEINS: 
Patients with CKD generally have reduced plasma HDL 
cholesterol concentration compared with nonuremic individuals. 
Because of the low apo-AI level and decreased LCAT activity, the 
esterification of free cholesterol and hence the conversion of HDL3 
to HDL2 are diminished in uremia. This decreased ability of the 
HDL particles to carry cholesterol leads to impairment in the 
reverse cholesterol transport from peripheral cells to the liver, 
thereby burdening the vasculature with cholesterol and promoting 
atherosclerosis39-41. 
Paraoxanase, a component of HDL, inhibits the oxidation of 
LDL. Plasma paraoxanase activity is reduced in patients with 
CKD42, thereby predisposing the LDL and possibly also 
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HDL particles to oxidation. Further uremia associated inflammation 
might convert HDL from an antioxidant into a prooxidant 
particle43,44. All of these may contribute to atherogenesis in CKD. 
LOW-DENSITY LIPOPROTEIN: 
Elevated plasma LDL cholesterol concentration is common in 
nephrotic syndromes. But it is not a typical feature of patients with 
advanced chronic kidney disease, especially who are on 
hemodialysis. But qualitative changes may occur in LDL in patients 
with CKD and dialysis patients. 
The proportion of small dense LDL and IDL which are 
considered to be highly atherogenic, are increased. Sd LDL is a 
subtype of LDL that has high propensity to penetrate the vessel 
wall, becomes oxidized and triggers atherosclerotic process. 
Since the hepatic lipase enzyme is decreased in HD patients, 
which degrades VLDL to IDL, IDL accumulates in plasma45. IDL 
and sd LDL have high affinity for macrophages, which theoretically 
promote their entry into the vascular wall to participate in the 
formation of foam cells and atherosclerotic plaques46-49. 
         A vicious cycle has been suggested in uremia in which the 
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decreased catabolism of IDL and LDL leads to their increased 
plasma residence time and further modification of apo B contained 
in these lipoproteins by oxidation, carbamylation and glycation. 
These modifications lead to reduced recognition and binding of 
those lipoproteins to LDL receptors50.                
TOTAL CHOLESTEROL 
          In a prospective study51 in 73 non diabetic patients with 
primary CKD,total cholesterol,LDL cholesterol and apolipoprotein 
B were signifigantly associated with a rapid decline in renal 
function.In another study52,among 104 patients with CKD who were 
followed up for a mean of 4.1 years,total cholesterol and urinary 
protein scores were positively related to the progression of renal 
disease. In the Choices for Healthy Outcomes in Caring for ESRD 
(CHOICE) study, which showed a nonsignificant negative association of 
cardiovascular mortality with plasma total as well as non–HDL 
cholesterol levels in the presence of inflammation and/or malnutrition ; in 
contrast, there was a positive association between total and non–HDL 
cholesterol and mortality in the absence of inflammation or malnutrition. 
These observations are compatible with the hypothesis that the inverse 
association of total cholesterol levels with mortality in dialysis patients is 
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mediated by the cholesterol-lowering effect of malnutrition and/or 
systemic inflammation and not due to a protective effect of high 
cholesterol concentrations53,54.But most studies state that 
hypercholesterolemia is not a common feature of CKD.It is commonly 
found in nephrotic syndrome. 
LIPOPROTEIN (a)  
Lipoprotein (a) is an LDL-like lipoprotein that consists of 
apo(a) that is covalently bound to an LDL particle. There are two 
isoforms of Lp(a) (i) large apo (a) isoform and (ii) small apo (a) 
isoform55. 
Most but not all studies showed that isoform specific  
increase in plasma Lp(a) levels seen in non-nephrotic patients with 
CKD56-61. 
Lp(a) contains 2 apolipoproteins. The production rates of 
apo(a) and apo(b) were normal in CKD patients whereas fractional 
catabolic rate of these apolipoproteins was significantly reduced in 
these patients. This resulted in longer residence time in plasma of 
almost 9 days for apo(a), compared with 4.4 days in control 
subjects. This decreased clearance is likely the result of loss of 
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kidney function in HD patients62. 
DYSLIPIDEMIA IN HEALTHY & SPECIAL POPULATION: 
Dyslipidemia in Young healthy adult Indian population: 
A study done by A.M. Sawant et al63 in 2006 at P.D. Hinduja 
Hospital, Mumbai, India showed that the total cholesterol 
concentration >200mg/dl was found in 38.7% of males and 23.3% 
of females. HDL-C was abnormally low in 64.2% males and 33.8% 
females. The increase in prevalence of hypercholesterolemia and 
hypertriglyceridemia was more prominent in 31-40 age group than 
in <30 age group. 
Dyslipidemia of Diabetes64 
In a hospital based study in Nagpur, India, the characteristic 
pattern of lipoproteins in type 2 diabetes includes an increase in 
triglycerides and decrease in HDL cholesterol. Concentrations of 
LDL cholesterol in diabetic individuals do not differ significantly 
from concentrations found in non-diabetic individuals but are 
predominated by the small dense form of LDL. The small dense 
LDL particles are more intrinsically atherogenic than the normal 
larger and more buoyant LDL particles. Furthermore because of 
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their smaller mass, a greater number of LDL particles are contained 
within the plasma of patients with small dense LDL, further 
increase the atherogenic risk. This triad of lipid abnormalities 
namely increased triglycerides and sd LDL and decreased HDL, has 
been termed “Diabetic Dyslipidemia”. 
Lipids in Haemodialysis and Peritoneal Dialysis65-68 
HD patients usually display increased concentrations of intact 
or partially metabolized triglyceride rich lipoproteins, reduced 
serum levels of HDL cholesterol and elevated concentrations of 
Lp(a). Total and LDL-cholesterol values are within normal limits or 
reduced in this patient population whereas the sub fractionation of 
apoliporotein B containing lipoproteins usually reveals of 
predominance of small, dense LDL particles. Use of high flux 
polysulfone membrane is accompanied by a significant reduction in 
serum triglyceride levels as well as by an increase in apolipoprotein 
AI, and HDL cholesterol levels . This improvement could be 
attributed to an increase in the apolipoprotein C-II/CIII ratio which 
increases the activity of lipoprotein lipase and facilitates the 
intravascular lipolysis of triglyceride rich lipoproteins . Heparin, 
used in HD, releases lipoprotein lipase from the endothelial surface 
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and thus its chronic use may result in lipoprotein lipase depletion 
and defective catabolism of triglyceride rich lipoproteins. 
It is well known that CAPD patients lose substantial amount 
of proteins into peritoneal dialysate. This protein loss may, in turn, 
stimulate hepatic production of albumin and cholesterol enriched 
lipoproteins thus leading to elevated concentrations of LDL 
cholesterol and Lp(a) . In addition, the absorption of glucose from 
the dialysis fluid and the resultant increase in insulin levels may 
enhance the hepatic synthesis and secretion of VLDL and possibly 
that of other lipoproteins such as Lp(a) . 
Lipids in renal transplant patients69 
These patients have elevated values of total cholesterol, 
VLDL, LDL cholesterol as well as increased concentration of 
triglycerides and apolipoprotein B . HDL cholesterol tends to 
increase in post transplant period and this change is attributed to 
the effects of corticosteroids. They also exhibit significant decrease 
in the concentrations of Lp(a) after renal transplantation. It has 
been shown that cyclosporine administration significantly increases 
the concentrations of LDL-C and TGL while it reduces the serum 
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values of HDL cholesterol . 
Treatment of dyslipidemia in CKD patients69 
Data from studies conducted in individuals with CKD suggest 
that the effect of these drugs on cardiovascular morbidity and 
mortality in these patients is significantly influenced by the severity 
of renal dysfunction. Thus in several large, prospective, placebo 
controlled trials of statins, post hoc analyses of subgroups with 
mild to moderate renal failure revealed a significant reduction in 
cardiovascular morbidity and mortality . The use of statins as a first 
line therapy for the prevention of ischemic events in dyslipidemic 
individuals with CKD (stage 1-3) seems to be safe, reasonable and 
evidence based.  
It has been proposed that the failure of statins in ESRD 
patients is due to the presence of micro inflammation and 
malnutrition in these individuals . 
Though fibrates induce shift in the LDL subfraction towards 
larger and more buoyant particles , in patients with renal failure 
they are associated with high risk of muscular toxicity . Fibrates 
should be used only in the patients with CKD who exhibit 
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extremely elevated triglyceride values (>500mg/dl). In these cases 
the risk of acute pancreatitis justifies the use of gemfibrozil as the 
fibrate of choice in individuals with impaired renal function . 
Efficiency of other drugs in patients with CKD and their 
impact on the cardiovascular risk in these patients were not studied 
well. 
 29
MATERIALS & METHODS 
This study was conducted in 50 patients with chronic kidney 
disease and 50 normal healthy persons. 
All the patients in this study group were selected from the 
outpatient department and those who were admitted to Institute of 
Internal Medicine, Madras Medical College Hospital during 
June2007 - June 2008. The controls were selected from the 
outpatient department who were accompanying the patients. 
STUDY DESIGN: Cross sectional observational study 
INCLUSION CRITERIA FOR PATIENTS 
1. Patients between age group of 15 to 80 years with chronic 
kidney disease. 
2. Patients with established chronic kidney disease were 
selected irrespective of the etiology. 
3. Patients who were on conservative or dialytic treatment for 
chronic kidney disease. 
4. Established renal failure was ensured by radiological 
evidence or biochemical evidence for more than 3 months. 
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EXCLUSION CRITERIA 
1. Patients with Acute renal failure and Nephrotic Syndrome 
2. Who are on drugs affecting lipid metabolism like  β 
blockers, statins and oral contraceptive pills. 
3. Female patients who were pregnant 
Written consent was obtained from both patients and controls. 
Detailed history regarding symptoms and duration of the 
kidney disease, hypertension, diabetes, smoking, alcoholism, drug 
intake and treatment were elicited. A detailed clinical examination 
was performed in all patients. Blood pressure, renal function tests, 
abdominal ultra sonogram and Electrocardiogram were done for all 
patients. 
After 12 hours of overnight fasting blood sample was taken 
for lipid profile from patients and controls. 
Patients with chronic kidney disease and controls included in 
the study were matched according to age and the results were 
analyzed. 
 
LABORATORY METHODS FOR ESTIMATING LIPIDS 
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HDL-C Estimation: (Erba Mannheim - XL System packs) 
HDL cholesterol was measured by using immunoinhibition 
method. The reagent contains 2 parts. First reagent (R1) inhibits 
lipoprotein fractions other than HDL-C. After adding reagent 
2(R2), a blue colour complex develops. The intensity of blue color 
complex formed at 593nm is proportional to the HDL-C in the 
sample. 
Principle  
LDL, VLDL & Chylomicrons in the sample were complexed 
with antibody present in the reagent 1 thereby HDL-C remains free 
to react with reagent 2. 
HDL cholesterol +H2O+O2  CHE & CO     4-Cholestenone+ Fatty Acid 
        
 in reagent 2  + H2O2 
H2O2 + DAOS + 4 AAP Peroxidase   - Blue colored complex +2H2O 
Cholesterol estimation (Autopack - Bayer) 
Cholesterol was estimated by enzymatic method. The reagent 
contains 2 parts. (R1 & R2). When R1 is added it forms hydrogen 
peroxide. This in turn reacts with phenol in R2 and forms red 
quinone. The intensity of red coloured complex is directly 
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proportional to the concentration of cholesterol in the sample. It is 
measured at 500nm. 
Principle: 
Cholesterol ester +H2O Cholesterol  Cholesterol + Fatty Acid 
         Esterase in R1 
Cholesterol+ O2 Cholesterol  Cholesterol + H2O2 
        Oxidase in R1 
H2O2+Phenol (R2) + 4 Aminoantipyrine (R1)  Red quinone + 4H2O 
TGL Estimation (Bayer Diagnostics) 
It was measured by enzymatic calorimetric method. The 
reagent contains 2 parts. When R1 is added to the sample, H2O2 is 
formed. This in turn reacts with R2 and forms red quinone. The 
intensity of purple colour is directly proportional to the triglyceride 
concentration in the sample and is measured at 546nm. 
Principle: 
   Lipoprotein 
Triglycerides +H2O   Glycerol + Fatty acid 
   Lipase in R1 
 
   Glycerol 
Glycerol+ ATP     Glycerol 3 Phosphate +ADP 
    Kinase R1 
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                                                GPO 
Glycerol 3 phosphate +O2     Dehydroxyacetone Phosphate
 in R1       + H2O2 
            Peroxidase 
2H2O2+ 4 aminoantipyrine(R1) +ADPS(R2)           Red quinone+4H2O
       
 
ADPS  = N ethyl N sulfopropyl n-anisidine. 
LDL was estimated by using Friedwald formula 
LDL = Total cholesterol - (HDL-C + TGL/5) 
Ultra sonogram showing reduced kidney size (<9cm) was 
taken as radiological evidence of chronic kidney disease. 
Electrocardiogram of all patients was studied in detail.  
Romhilt- Estes criteria was applied for finding out left 
ventricular hypertrophy. 
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ROMHILT ESTES SCORING SYSTEM FOR LVH 
  Points 
1. R or S wave in any limb lead ≥ 2mv 3 
 or S in lead V1 or V2  
 or R in lead V5 or V6 ≥ 3mv  
2. Left Ventricular strain  
 ST segment and T wave in opposite direction 
to QRS complex 
 
 Without digitalis 3 
 With digitalis 1 
3. Left atrial enlargement  
 Terminal negativity of the P wave 3 
 in lead V1 is ≥ 0.10 mV in depth  
 and ≥ 0.04 S in duration  
4. Left axis deviation ≥ -30 degrees 1 
5. QRS duration ≥ 0.09 seconds 1 
6. Intrinsicoid deflection in lead  
 V5 or V6 ≥ 0.05 S 1 
 Maximally attainable 13 
 
 LVH - 5 points  
 
Probable LVH-4 points 
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ATP - III NCEP guidelines were applied to the lipid profile. 
ATP III CLASSIFICATION OF LDL, TOTAL AND HDL 
CHOLESTEROL AND TRIGLYCERIDES 
TOTAL CHOLESTEROL 
<200 Desirable 
200-239 Borderline high 
>240 High 
 
LDL CHOLESTEROL 
<100 OPTIONAL 
100-129 Near or above normal 
130-159 Border line High 
>160 High 
 
HDL CHOLESTEROL 
<40 Low 
>60 High 
 
TRIGLYCERIDES 
<150 Normal 
150-199 Borderline high 
200-499 High 
≥500 Very high 
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In this study 
LDL > 130 mg/dl 
HDL < 40 mg/dl 
TGL > 200 mg/dl 
TC > 240 mg/dl were considered abnormal 
STATISTICAL METHODS 
Mean values were obtained for LDL, HDL, TGL & Total 
cholesterol separately. Then standard deviations were calculated for 
each category of observations for both study and control group. 
Mean deviation, standard error of difference between two means 
was calculated. If the standard error of difference between two 
means is more than two times that of actual difference between two 
means it will be taken as significant value. Students T test was 
performed & T value was obtained. P value from t value was 
calculated. P value of <0.05 was considered significant 
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RESULTS AND OBSERVATIONS 
AGE DISTRIBUTION 
Age of the patients varied from 14 yrs to 80 yrs. Majority of 
patients fall in the age group between 26-55 years. Seventy two 
percentage of people contribute this group. 
AGE DISTRIBUTION IN PATIENTS 
Age in years No. of Patients Percentage 
15-25 2 4% 
26-35 13 26% 
36-45 11 22% 
46-55 12 24% 
56-65 10 20% 
66-75 1 2% 
>75 1 2% 
SEX DISTRIBUTION 
Males constitute 34(68%) and females constitute 16(32%) in 
this study. 
EDUCATIONAL STATUS 
Majority of patients were illiterate (23 persons) (46%). 
Patients studied higher than HSc were 6 persons (12%). Others 
studied between 5th std to 10th std. 
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OCCUPATION 
Patients in this study  belonged to low socioeconomical status 
which is being reflected by their occupations. A quarter of the 
patients were doing agriculture or agriculture related profession. 
Most women were home makers. 
PERSONAL HABITS 
In this study 40% (20 patients) of the patients were smokers 
and 42 % (21 patients) were alcoholics. 
RENAL PARAMETERS 
Lowest urea value found in these patients was 17mg/dl and 
the highest was 230 mg/dl. Creatinine values ranged between 0.5 
mg/dl to 22.6 mg/dl. Mean values of creatinine was 6.74 ± 4.77 
mg/dl. 
BLOOD PRESSURE READINGS 
Patients with blood pressure of more than 140/90 were 
considered hypertensives. Most patients (39 patients) were 
hypertensives at the time of presentation. Only 11 patients had 
blood pressure less than 140/90mmHg.  
 
DIABETIC STATUS 
 39
It was found that 22 patients (44%) were diabetic and their 
random blood sugar levels ranged from 51mg/dl to 388 mg/dl. 
TREATMENT SCENARIO 
Among the 50 patients, 33 patients (66%) were on 
conservative treatment only, 10 patients (20%) received peritoneal 
dialysis, 7 patients (14%) received hemodialysis. Out of the 10 
patients who underwent PD, 7 patients underwent PD earlier than 1 
month ago and only  3 patients were treated with PD during the 
time of admission. In the HD group, 4 patients underwent  dialytic 
treatment a week before admission whereas other 3 received more 
than a month ago. 66% patients were treated with drugs only. 
During our study no patients were admitted with history of previous 
transplantation. 
RADIOLOGICAL EXAMINATION 
Radiological examination was done by abdominal ultra 
sonogram. In 38 patients the kidney size was less than 9cm in one 
or both kidneys. Rest of them (12 patients) showed normal kidney 
size in USG. 
 
ECG RESULTS 
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Patient’s electrocardiograms were analysed. It was found that 
15 patients (30%) showed left ventricular hypertrophy. 10 patients 
(30%) showed ischemic changes. 3 patients showed tall peaked T 
waves. 
ECG CHANGES IN CKD PATIENTS (STUDY GROUP) 
Type of ECG changes Males Females Combined 
LVH 10(20%) 5(10%) 15(30%) 
Ischemia 6(12%) 4(8%) 10(20%) 
CKD PATIENTS WITH LVH SHOWING LIPID 
ABNORMALITIES (STUDY GROUP)  
Type of lipid Disorders Number of Patients  (out of 15) Percentage 
Elevated Cholesterol 3 20% 
Elevated Triglycerides 4 27% 
Decreased HDL 10 67% 
Increased LDL Cholesterol 10 67% 
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CKD PATIENTS WITH ISCHEMIA SHOWED THE FOLLOWING 
LIPID DISORDER 
Type of lipid Disorders Number of Patients  (our of 10) Percentage 
Elevated Cholesterol 3 30% 
Elevated Triglycerides 7 70% 
Decreased HDL 6 60% 
Increased LDL Cholesterol 6 60% 
LIPID PATTERN IN OUR STUDY 
HDL PATTERN 
Serum HDL values ranged between 30mg/dl to 80mg/dl. 
Patients showed abnormal HDL levels (<40 mg/dl) were 25 (50%). 
Its mean value was 42.82 and standard deviation was 12.25. Among 
the control groups, the lowest value of HDL was 46 mg/dl and the 
highest was 65 mg/dl. Their mean was 54.20 and standard deviation 
was 4.18. Mean deviation and standard error of difference between 
two means were calculated. Actual difference between two mean 
was 8.07 and the standard error of difference between two means 
was 1.83. This was statistically significant since the actual 
difference was two times higher than the standard error of 
 42
difference between two means. T value was calculated using 
student’s t test. It was 6.2169. P value (<0.05) was statistically 
significant. It showed that there was a significant reduction in 
HDL-C levels in patients with CKD than that of controls. 
MEAN AND STANDARD DEVIATION OF LIPID FRACTIONS IN 
50 CKD PATIENTS IN THE STUDY 
 
Total 
Cholesterol 
mg/dl 
Triglycerides 
mg/dl 
Low 
Density 
Lipoprotein 
mg/dl 
High 
Density 
Lipoprotein 
mg/dl 
Mean 209.3 171.2 131.7 42.82 
Standard 
Deviation 
42.9 86.45 25.71 12.25 
MEAN AND STANDARD DEVIATION OF LIPID  
FRACTIONS IN 50 CONTROLS 
 
Total 
Cholesterol 
mg/dl  
Triglycerides 
mg/dl   
Low 
Density 
Lipoprotein 
mg/dl  
 High 
Density 
Lipoprotein 
mg/dl  
Mean  185.2 102.2 112.5 54.20 
Standard 
Deviation 15.2 7.75 13.42 4.18 
 
 43
STANDARD ERROR OF DIFFERENCE BETWEEN  
TWO MEANS AND P VALUES 
 
Total 
Cholesterol 
mg/dl  
Triglycerides 
mg/dl    
Low 
Density 
Lipoprotein 
mg/dl  
High 
Density 
Lipoprotein 
mg/dl  
Standard 
error of 
Difference 
between 
two means 
6.44 12.28 3.61 1.83 
P values <0.05 <0.05 <0.05 <0.05 
LDL PATTERN 
Lowest value of LDL 65 mg/dl and the highest value was 
173mg/dl. Abnormally high LDL levels (>130mg/dl) were found in 
22 patients and they constitute 44%. Their mean value was 131.7 
mg/dl and standard deviation was 25.71.In controls, the mean and 
SD were 112.5 and 13.42 (Range 85 - 150mg) respectively. 
Standard error of difference between two means was 3.61. 
Actual difference between two means was 19.2 which were (20%) 
two times greater than the standard error of difference between two 
means. Student t value was calculated (t=4.6813) and P value was  
(< 0.05) significant. 
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TGL PATTERN 
TGL value in our study group ranged between 95 mg/dl to 
350 mg/dl. Range of TGL value in control group was 90mg/dl to 
122mg/dl. TGL levels were abnormal in 24 patients (>200mg/dl). 
Mean and standard deviation of study group were 171.2 and 86.45 
respectively. In controls, the mean and standard deviation were 
102.2 and 7.75. Student‘t’ test was performed and t value was 
calculated (t=5.6212). P value was significant (P < 0.05) 
TOTAL CHOLESTEROL 
Range of TC levels in study group was 120mg/dl to 258 
mg/dl. Lowest value in control group was 119 and the highest value 
was 222mg/dl. Total cholesterol was more than 240mg/dl in 10 
patients (20%). The mean values of study group and control group 
were 209.3 and 185.2mg/dl respectively. Their standard deviations 
were 42.9 and 15.2 respectively. Standard error of difference 
between two means was obtained. It was 6.44 but the actual 
difference was 124.1 which was more than two times higher than 
that of standard error of difference between the two means. T value 
was calculated (t =3.7442). P value was (P<0.05) significant. 
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CORRELATION STUDIES 
CORRELATION BETWEEN LIPID FRACTIONS AND  
SERUM CREATININE IN PATIENTS 
Lipid Fraction Correlation coefficient with Creatinine P Value 
TC +0.12469 N.S 
TGL +0.23731 <0.05 
HDL -0.28328 N.S 
LDL +0.21606 N.S 
N.S - Not Significant 
Correlation coefficient between serum creatinine and various 
lipid fractions were calculated. 
Correlation coefficient between serum creatinine and LDL 
was +0.216 which was a positive correlation. 
Correlation coefficient between HDL and creatinine was – 
0.286, which was a negative correlation. 
Correlation coefficient between creatinine and TG was 
+0.124 which was a positive correlation. 
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Correlation coefficient between creatinine and total 
cholesterol was +0.12469, which was a positive correlation. 
P values from the correlation coefficient were calculated. 
P value of correlation coefficient between serum creatinine 
and HDL levels was statistically significant in the study group. It 
indicates that there is a negative linear relationship exists between 
HDL values and serum creatinine (i.e. when creatinine value raises 
HDL value falls).  
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DISCUSSION 
In our study, most common lipid abnormalities found were 
low HDL levels (50%) and hypertriglyceridemia (48%). 
COMPARISON OF LIPID PROFILE BETWEEN OTHER 
STUDIES AND OUR STUDY 
Studies  TGL LDL HDL TC 
Shah 
et al 
S 222.78±90.08 109.63±36.51 52.69±16.36 211.33±40.33 
 C 121.78±64.89 140.33±23.34 44.22±10.33 184.11±18.79 
Diana 
M lee 
et al 
S 194.05±106.28 170.148±50.27 38.6±11.6 239.75±61.8 
 C 106.28±26.5 131.47±30.93 42.53±7.73 189.14±30.93 
Our 
study 
S 171.2±86.45 131.7±25.71 42.82±12.25 209.3±42.9 
 C 102±7.5 112.5±13.42 54.20±4.18 185.2±15.2 
S- Study Group C-Control Group 
DECREASED HIGH DENSITY LIPOPROTEIN LEVELS 
The low HDL levels in patients with chronic kidney disease 
in our study were consistent with Diana M Lee LG et al70 who 
studied the lipid profile in CRF patients. 
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This low HDL cholesterol levels were also an independent 
risk factor for the development of CKD in the Framingham off 
spring study.  
Several mechanisms may underlie these reductions in HDL 
cholesterol levels, which is usually an indication of impaired 
reverse cholesterol transport. Thus, uremic patients usually exhibit 
decreased levels of apolipoprotein AI & AII (the main protein 
constituent of HDL). Diminished activity of LCAT (the enzyme 
responsible for the esterification of free cholesterol in HDL 
particles) as well as increased activity of cholesterol ester transfer 
protein that facilitates the transfer of cholesterol esters from HDL 
to TGL rich lipoproteins that reduce serum concentrations of HDL 
cholesterol69. 
In MDRD study71, low HDL levels in CKD patients were one 
of the independent risk factor for progression of kidney disease. 
Though in our study the mean value was 42.82, it is significantly 
less than the age matched healthy controls.  
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VARIOUS STUDIES ON PROGRESSION OF KIDNEY DISEASE 
AND ASSOCIATED PLASMA LIPID ABNORMALITIES: 
Study Patients Number of patients 
Follow 
up Lipid 
MDRD CKD 840 2.2 
YRS 
↓HDL 
Samuelsson O 
et al 
CKD 73 3.2 
YRS 
↑TCh, ↑LDL, 
↑ApoB 
Locatelli et al CKD 456 2 YRS No relationship 
Massy ZA et 
al 
CKD 138 12 YRS ↑TG, ↓HDL 
ELEVATED TRIGLYCERIDES  
Hypertriglyceridemia was observed in 48% of patients. 
Triglyceride levels were significantly elevated in our study than 
control group. Abnormal triglyceride values were found in 48% of 
patients in our study. Shah et al72 & most western studies 
demonstrated that hypertriglyceridemia was the abnormality found 
in CKD patients. Gupta DK et al6, Das BS et al7, Bagdade J73, 
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Chan MK et al74 also found hypertriglyceridemia was the major 
abnormality in their studies. 
Hypertriglyceridemia represents an early feature of renal 
failure. Indeed previous studies have shown that patients with 
impaired renal function exhibit increased concentrations of 
triglycerides even though serum creatinine levels were within 
normal limits. 
In addition, individuals with renal insufficiency, usually 
display abnormal increase in serum triglycerides levels after a fat 
meal (post prandial lipemia). Experimental studies revealed that 
accumulation of triglyceride rich lipoprotein (VLDL, chylomicrons 
and their remnants) in individuals with predialysis CKD is mainly 
due to their decreased catabolism. The down regulation of the 
expression of several genes along with the changes in the 
composition of lipoprotein particles and the direct inhibitory effect 
of various uremic toxins on the enzymes involved in lipid 
metabolism represent the most important pathophysiological 
mechanism underlying the development of hypertriglyceridemia in 
renal failure. Interestingly, it has been proposed that secondary 
hyperparathyroidism may also contribute to the impaired 
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catabolism of triglyceride rich lipoproteins and that 
parathyroidectomy or the administration of calcium channel blocker 
verapamil may partially ameliorate the hypertriglyceridemia of 
CKD. It is well known that impaired insulin sensitivity represents 
an early feature of CKD. Thus it could be due to insulin resistance 
driven over production of VLDL may significantly contribute to the 
development of hypertriglyceridemia in CKD patients70. 
ELEVATED LOW DENSITY LIPOPROTEIN 
LDL was significantly elevated than that of controls in our 
study. We found that 44% of patients showed elevated LDL levels. 
This observation is similar to the studies of Diana M Lee et al. In 
an article published in archives of internal medicine75 32 patients 
were studied and compared the lipid profile on CKD and non CKD 
patients. It was found that 60.5% of patients have elevated LDL-C 
than non CKD patients (P=0.06). But most studies find that Uremic 
Patients usually have normal or slightly reduced concentrations of 
LDL-C levels and they exhibit important disturbance in the density 
distribution of LDL sub fraction that is characterized by a 
predominance of small dense LDL particles76-80. 
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In our study, this elevated LDL-C may be due to the 
inaccuracy of Friedwald formula in estimating LDL cholesterol. 
Another contributing factor is that peritoneal dialysis may increase 
LDL-C due to the compensatory production of lipoprotein in 
response to protein loss during the procedure. 
Total Cholesterol: 
Total cholesterol levels were significantly elevated in our 
study group. We observed the same findings in the study by Diana 
Lee M et al. But most of the studies did not observe 
hypercholesterolemia. The possible reason for the hypercholesterolemia 
in our study is significant elevation of cholesterol containing lipid 
fractions (IDL, LDL).  
Correlation Studies: 
It was found that serum triglycerides, TC, LDL, were not 
correlated significantly whereas serum HDL levels had significant 
negative correlation with serum creatinine. It means that when 
serum creatinine level rises, serum HDL level falls. This was the 
observation found in MDRD study.  
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ECG changes: 
Out of 50 patients, 30% of patients showed changes 
suggestive of LVH and 20% of patients showed ischemic changes. 
This observation was similar to study done by Levin et al. The risk 
of dying of cardiac complications is 65 times higher in dialysis 
patients between 45-54 years and 500 times higher than the general 
population. The risk factors which are responsible for increased 
morbidity and mortality were hypertension, DM, high LDL, low 
HDL, smoking, LVH, male gender, old age, anemia, hypervolemia, 
insulin resistance and proteinuria.  
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CONCLUSION 
1. HDL-C levels were lower and triglycerides, total 
cholesterol and LDL-C levels were higher in the study 
group compared to controls. All were statistically 
significant. 
2. Predominant lipid abnormality was reduced HDL-C 
levels. 
3. There was a negative correlation exists between serum 
HDL-C level and serum creatinine levels which was 
statistically significant. 
4. Percentage of patients showing ECG changes of left 
ventricular hypertrophy and ischemia were 30% and 
20% respectively. 
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LIMITATIONS OF THE STUDY 
1. Most studies showed low or normal LDL-C levels 
whereas this study observed significantly elevated 
LDL-C levels for reasons little known. 
2. Smoking, alcoholism and diabetics may alter the lipid 
pattern in the body. Their influences in the study group 
also have to be considered. 
3. Since we had not analysed the echocardiogram of the 
patients, the real scenario of ischemia in CKD patients 
who had not shown any abnormality in ECG was not 
known. 
4. We had not estimated the lipid abnormalities in patients 
who underwent dialytic treatment since most of them 
were irregular in their treatment. 
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LIPID PROFILE IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE 
Sl. 
No Name Age Sex HDL LDL TGL TC 
1. Narayanan 44 M 80 126 180 242 
2. Guthigan 44 M 42 150 230 238 
3. Sundaramoorthy 30 M 55 120 146 206 
4. Kumar 27 M 32 162 220 238 
5. Subrammani 65 M 50 128 214 220 
6. Babu Sethu 32 M 32 126 96 177.2 
7. Shankar 30 M 68 146 220 258 
8. Chokkammal 45 F 35 119 110 176 
9. Amaravathy 65 F 35 65 104 120.8 
10. Suseela 30 F 30 140 350 240 
11. Narayana Samy 55 M 45 168 160 245 
12. Mariyan Beevi 60 F 76 130 185 243 
13. Kumar 29 M 32 156.8 106 210 
14. Banu 27 F 48 128 150 206 
15. Chinna Ponnu 45 F 45 151 220 240 
16. Chinna Samy 55 M 40 148 235 235 
17. Saratha 37 F 48 130 200 218 
18. Ponmudi 52 M 35 65 104 120 
19. Sithiraj 55 M 32 85 95 136 
20. Ibrahim 38 M 42 86 110 152 
21. Vasantha Kumar 24 M 36 150 240 234 
22. Marimuthu 50 M 42 147 200 229 
23. Kondai raj 32 M 76 125 190 239 
24. Panja charam 64 M 40 126 130 202 
25. Selvi 40 F 40 123 210 205 
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Sl. 
No Name Age Sex HDL LDL TGL TC 
26. Ramu 60 M 36 131 235 214 
27. Saratha 35 F 38 158 260 248 
28. Ramachandran 80 M 40 167 158 238 
29. Kalyanam 40 M 36 112 100 168 
30. Lurthu samy 50 M 36 110 110 168 
31. Orammal 55 F 40 149 206 230 
32. Siva Kumar 38 M 36 158 220 238 
33. Geetha 45 F 36 160 228 241.6 
34. Jeveula 70 M 36 112 100 168 
35. Mani 52 M 40 122 209 222 
36. Senthil 29 M 36 135 95 190 
37. Govindaraj 55 M 40 167.8 136 235 
38. Arumugam 60 M 73 125 218 242 
39. Vasantha 35 F 40 126 200 202 
40. Ellappan 57 M 35 119 110 176 
41. Perumal 70 M 39 148 200 227 
42. Vijayalakshmi 47 F 38 173 95 230 
43. Kannagi 40 F 36 112 100 168 
44. Ramesh 32 M 38 149 205 228 
45. Rajathi 38 F 36 110 110 168 
46. Mathivanan 50 M 38 170 136 235.5 
47. Kalaiyarasan 35 M 66 148 205 255 
48. Ayyaru 65 M 40 128 208 209.6 
49. Pichai Kannu 60 M 36 66 104 122.8 
50. Anjammal 56 F 40 128 206 210 
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LIPID PROFILE IN CONTROLS 
S.No Name Age/Sex TGL mg% LDL mg% HDL mg% TL mg% 
1. Anbuselvam 35/M 106 108 58 186.8 
2. Ponnammal 47/F 95 120 55 194 
3. Kumar 37/M 90 128 50 196 
4. Parimala 40/F 105 114 60 195 
5. Karitha 22/F 110 150 50 222 
6. Raju 60/M 95 125 55 119 
7. Chinnakannu 72/M 90 128 58 204 
8. Gangadharan 48/M 115 106 65 194 
9. Deva Anbu 37/M 106 107 50 178.2 
10. Sironmani 42/M 102 103 53 176.4 
11. Kannaiya 54/M 115 110 54 176.4 
12. Subramaniyan 38/M 90 120 50 187 
13. Rajeshkumar 25/M 105 110 60 191 
14. Maniyammal 39/F 102 124 56 200.4 
15. Bharathi Devi 28/M 100 115 54 189 
16. Neela 47/F 100 85 55 160 
17. Panneerselvam 50/M 102 103 55 178 
18. Velmurugan 33/M 96 128 50 192 
19. Poongothai 37/F 100 125 55 200 
20. Savithiri 35/F 116 102 55 180 
21. Sadasivam 37/M 90 120 50 180 
22. Perumal 47/M 112 100 50 188 
23. Selvi 30/F 96 128 51 (50) 192 
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24. Nalini 31/F 95 116 58 193 
25. Murugesan 62/M 100 125 55 201 
26. Pavithra 19/F 116 102 55 180 
27. Narmatha 33/F 102 104 56 180.4 
28. Kaliyaperumal 75/M 90 120 50 188 
29. Pitchaikannu 47/M 94 120 55 193.8 
30. David 39/M 96 104 55 178.2 
31. Gunasekaran 34/M 98 103 55 177.6 
32. Harini 27/F 100 128 46 194 
33. Veerasekar 67/M 104 98 60 178.8 
34. Vikram 38/M 103 98 60 178.8 
35. Elangovan 35/M 98 98 56 173.6 
36. Pathiyammal 78/F 109 100 58 179.8 
37. Porselvi 40/F 110 114 60 196 
38. Kanagavalli 26/F 98 100 54 1736 
39. Muthukumar 24/M 100 106 49 175 
40. Stalin 30/M 104 90 48 158.8 
41. Sampathkumar 37/M 102 108 58 186.4 
42. Nagarani 55/F 105 90 56 167.0 
43. Anjammal 58/F 110 92 58 172 
44. Valli 43/F 100 106 55 180 
45. Vadivammal 58/F 106 105 55 182 
46. Ravi 38/M 122 124 50 198 
47. Mathialagan 50/M 118 107 50 180 
48. Govindaraju 56/M 100 128 48 196 
49. Kalaivanan 29/M 95 143 48 210 
50. Vani 32/M 96 125 50 194.2 
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PROFORMA 
No.:  
Name:  Age/Sex  I.P. No. DOA  Date 
Unit:    Education:   Occupation: 
RFT 
Sugar  Na+  TC  PCV 
Urea  K+  DC  P  L  E Hb 
Creatinine   ESR  Platelets 
USG Abdomen: RK   PCS    
LK   PCS   Pancreas 
 Other Findings 
BP Status    Glycemic Status 
Drugs 
Duration of DM  - Drugs/Insulin/Nil 
Duration of HTN  - Drugs/No Drugs/Irregular 
Other causes of CKD 
H/o Smoking    Symptoms  Signs 
H/o Alcoholism 
Family H/o Kidney Disease: DM / HTN 
Daily urine volume now: 
On drugs only  /  PD  /  HD /  Transplant - If dialysis no. of 
times       last dialysis  
     Date of Transplant 
ECG    ECHO if done 
Lipids: TGL  TC  HDL  LDL 
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1. Narayanan 44 M 65815 8th Std Leather 
Works 
+ - 11.5 3.6 48 1.8 60 150/100 – +  80 126 180 242 10 11 N N 
2. Guthigan 52 M 65178 – Agri + + 120 5 44 1.8 66 150/100 – – Drugs 42 150 230 238 10 9.5 N N 
3. Sundaramoorthy 30 M 70240 – Wood cutter – – 138 3.8 55 3.6 55 120/70 – – HD/ 5 
days 
ago 
55 120 146 206 8.1 8.1 Dilated/ 
B/L 
N 
4. Kumar 27 M 70208 – Painter – + 118 4.2 230 14.5 110 160/100 – + PD / 2 
months 
32 162 220 238 8.5 7.2 N T ↓ V1-V4 
5. Subrammani 65 M 67166 2nd 
std 
Agri + + 130 4 70 2.8 136 130/100 + + PD / 1 
month 
50 128 214 220 7.5 8.8 N LVH with 
I, avl; ST↓ 
V5-V6 
6. Babu Sethu 32 M 65742 SSLC Flower 
Business 
– + 126 5 192 22.6 80 160/100 – +  Drugs 32 126 96 177.2 7.5 7.3 N LVH with 
strain 
7. Shankar 30 M 67047 SSLC Driver – – 134 4 135 12.3 95 180/110 + + HD/ 4 
days 
68 146 220 258 8.5 8.8 N LVH 
8. Chokkammal 45 F 66802 – Home 
maker 
– – 118 6 47 1.5 51 90/60 + – Drugs 35 119 110 176 10.2 8.9 N Sinus tachy 
cardia 
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9. Amaravathy 65 F 66803 – Home 
maker 
– – 127 4.8 64 2.3 192 160/100 + + Drugs 35 65 104 120.8 8.5 9.8 N N 
10. Suseela 30 F 66312 – Home 
maker 
– – Low 4.5 151 13.9 57 160/100 – – PD/ 1 
month 
30 140 350 240 7.3 7.1 N N 
11. Narayana Samy 55 M 68068 – Agri – – 118 5.6 192 12 94 180/100 + – PD/ 2 
months 
45 168 160 245 6.2 6.3 N LVH with 
ST↓ II, III, 
AVF 
12. Mariyan Beevi 60 F 67653 – Home 
maker 
– – 126 4.9 68 2.5 104 190/100 + + Drugs 76 130 185 243 10.3 11.7 N LAD/ LVH 
13. Kumar 29 M 67957 8th std Business + + 132 4.2 221 14.3 100 240/140 – – Drugs 32 156.8 1.6 210 7.6 8 N LVH 
14. Banu 27 F 68271 7th std Agri – – Low 5.9 174 11.3 135 150/80 – + Drugs 48 128 150 206 8.2 8.3 N LVH / T↓ 
V4-V6 
15. Chinna Ponnu 45 F 68307 – Agri – – 133 5.8 76 3.6 118 140/90 + – Drugs 45 151 220 240 7.1 7.6 N N 
16. Chinna Samy 55 M 71885 SSLC Agri – – Low 5 148 2.9 102 140/100 – + PD/ 3 
months 
40 148 235 235 7.2 7.5 N T ↓ I, 
AVL; QS 
V1-V6 
17. Saratha 37 F 69638 5th std Home 
Maker 
– – 130 4.8 116 5 96 160/90 – – PD/ 2 
months 
48 130 200 218 7.8 7.2 N N 
18. Ponmudi 52 M 72136 – Construction 
worker 
+ + 110 3.2 120 4.8 82 150/100 – + HD 1 
day 
35 65 104 120 8.4 83.6 N N 
19. Sithiraj 55 M 68411 – Agri + + 128 4 79 2.8 92 130/90 – + Drugs 32 85 95 136 9.4 9 N Low 
voltage 
complex 
20. Ibrahim 38 M 66059 8th std Leathar 
worker 
– – 115 3.5 140 8 154 130/60 – – Drugs 42 86 110 152 12 12 N N 
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21. Vasantha 
Kumar 
24 M 66105 B 
com 
BPO – – 128 6.4 185 21.2 200 200/110 – – Drugs 36 150 240 234 6.9 7.2 N N 
22. Marimuthu 50 M 70221 12th 
std 
Agri + + 118 5.3 123 7.4 129 140/100 + – HD/1 
month 
42 147 200 229 11.4 11.3 N Tall T 
Waves 
23. Kondai raj 32 M 65293 4th std Load man + + 124 3.8 17 0.5 100 190/120 – – HD/ 
regular 
76 125 190 239 8.3 7.8 N LVH 
24. Panja charam 64 M 65007 8th std Lorry  
driver 
+ + 131 5.7 102 5.6 104 130/80 – + Drugs 40 126 130 202 7 8.1 N Sinus 
Brady 
cardia 
25. Selvi 40 F 66057 – Home 
maker 
– – 124 5.1 68 5.6 388 130/100 + + Drugs 40 123 210 205 8.4 7.2 N ST↓ I; 
AVL, V5-
V6 
26. Ramu 60 M 66032 5th std Washer man – – 118 6.2 177 14.6 122 200/120 – – Drugs 36 131 235 214 7.8 7.4 N Tall T 
waves 
27. Saratha 35 F 64541 – Home 
maker 
– – 131 4 176 10.2 97 200/120 + – PD/ 5 
days 
38 158 260 248 8.1 9.6 N Poor 
progression 
R wave, 
V1-V3 
28. Ramachandran 80 M 70055 3rd std Agri + + 124 3 112 5.6 80 140/90 + + Drugs 40 167 158 238 6.8 7.2 N LVH 
29. Kalyanam 40 M 70118 7th std Agri + – 128 5 76 3.4 132 221/50 + – Drugs 36 112 100 168 9.4 9.8 N N 
30. Lurthu samy 50 M 69928 6th std Mason – – 128 3.2 143 7.6 72 150/90 + + Drugs 36 110 110 168 6.1 6.3 N N 
31. Orammal 55 F 65139 9th std Home 
maker 
– – 116 5.5 120 6 120 140/90 + + Drugs 40 149 206 230 10.1 10.8 N LVH 
32. Siva Kumar 38 M 68315 12th 
std 
Agri + + 130 5 148 7 110 150/100 – + Drugs 36 158 220 238 7.1 7.8 N N 
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std 
33. Geetha 45 F 67412 PUC Home 
maker 
– – 116 3.8 110 5.8 100 130/100 – – Drugs 36 160 228 241.6 8.2 7.8 N N 
34. Jeveula 17 M 72163 10th 
std 
Carpenter – – 118 5 100 5.5 106 130/80 – + Drugs 36 112 100 168 6.8 7.1 N LVH 
35. Mani 52 M 66034 – Business + + 126 5 140 7 150 200/100 + + HD/ 2 
months 
40 122 209 222 9.8 10.4 N N 
36. Senthil 29 M 70106 BSc Clerk – + Low 6 124 7 128 140/100 + + Drugs 36 135 95 190 7.8 11.2 N LVH 
37. Govindaraj 55 M 67875 7th std Steel work + – 130 5.6 112 5.5 80 200/120 + – Drugs 40 167.8 136 235 6.4 7.2 N T ↓ V4-V6 
38. Arumugam 60 M 68130 5th std Painter + + 127 4.8 120 6 110 140/90 + + PD/3 
days 
73 120 218 242 9 10.2 N ST ↓ V1-
V4 
39. Vasantha 35 F 65235 SSLC Home 
Maker 
– – 130 7 140 6.7 78 190/120 – + Drugs 40 126 200 202 8.4 8.6 N Tall T 
waves 
40. Ellappan 57 M 67315 – Agri + + 116 4.5 148 7 112 150/100 – + PD/1 
month 
35 119 110 176 6.9 7.4 N N 
41. Perumal 70 M 68112 – Mason + + 130 5 112 6 100 130/90 – + Drugs 39 148 200 227 7.1 7.8 N N 
42. Vijayalakshmi 47 F 68306 – Construction 
worker 
– – 134 4 70 3 90 150/90 – + Drugs 38 173 95 230 7.4 9 N PRWP V1-
V4 
43. Kannagi 40 F 66720 7th std Agri – – 116 3.9 123 5.4 116 130/90 – – Drugs 36 112 100 168 8 8.2 N N 
44. Ramesh 32 M 64535 BA Business – – 124 5 110 2.8 138 146/90 + – HD/3 
months 
38 149 205 228 10.2 10.8 N N 
45. Rajathi 38 F 65175 – Home 
maker 
– – 138 5 88 3.5 105 140/100 – + Drugs 36 110 110 168 7.4 7.2 N LVH 
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46. Mathivanan 50 M 62252 9th std Agri + + 135 4 140 2.6 106 200/110 + + Drugs 38 170 136 235.5 6.5 7.8 N LVH 
47. Kalaiyarasan 35 M 38420 SSLC Mechanic – + 110 4.8 112 4 130 170/90 + + PD/ 2 
days 
66 148 205 255 11.5 10.8 N N 
48. Ayyaru 65 M 72015 – Agri + + 128 5 170 5.8 70 190/100 – + Drugs 40 128 20 209.6 7.8 8 N N 
49. Pichai Kannu 60 M 67210 6th std Agir + + 130 4.5 120 3.8 108 138/80 – + Drugs 36 66 104 122.8 8.8 9.2 N N 
50. Anjammal 56 F 71112 – Home 
Maker 
– – 110 6 205 12.4 136 170/90 + + Drugs 40 128 206 210 8.7 7.8 N LVH 
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ACRONYMS 
Apo - Apolipoprotein 
BP - Blood Pressure 
CC - Correlation Coefficient 
CKD - Chronic Kidney Disease 
CVD - Cardio Vascular Disease 
DM - Diabetes Mellitus 
ECG - Electro Cardiogram 
ESRD - End Stage Renal Disease 
FFA - Free Fatty Acid 
GFR - Glomerular Filteration Rate 
HD - Hemodialysis 
HDL-C - High Density Lipoprotein Cholesterol 
HTN - Hypertension 
IDL-C - Intermediate Density Lipoprotein Cholesterol  
IP No - In Patient Number 
K+ - Potassium 
K/DOQI - Kidney Disease Outcome Quality Initiative 
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LCAT - Lecithin Cholesterol Acyl Transferase 
LDL-C - Low Density Lipoprotein Cholesterol 
LK - Left Kidney 
LPL - Lipoprotein Lipase 
LRP - Low Density Lipoprotein Related Protein 
LVH - Left Ventricular Hypertrophy 
MDRD study - Modification of Diet in Renal Disease study 
Na+ - Sodium 
OXL-DL - Oxidised LDL 
PCS - Pelvic Calyceal System 
PD - Peritoneal Dialysis 
PMP  - Per Million Population 
RK - Right Kidney 
Sd LDL - Small Dense Low Density Lipoprotein 
TC - Total Cholesterol 
TGL/TG - Triglycerides 
USG - Ultra Sonogram 
VLDL-C - Very Low Density Lipoprotein Cholesterol 
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